Business Context and Reporting Period
Indaptus Therapeutics, Inc. (INDP) filed a Form 8-K on June 12, 2025, reporting the closing of a private placement of securities. The company, incorporated in Delaware and listed on the Nasdaq Capital Market, is a clinical-stage biopharmaceutical company focused on research and development.
Key Financial Metrics and Transaction Details
- Gross Proceeds: $2.3 million raised from the initial closing of the private placement.
- Instrument: Convertible promissory notes (the "Notes") with an aggregate principal amount of $2.3 million.
- Interest Rate: 6% per annum.
- Maturity Date: July 28, 2026.
- Conversion Terms: Notes convert to common stock at 80% of the average Nasdaq closing price for the five trading days preceding the conversion date, subject to a maximum conversion price of $0.40 per share.
- Warrants: Purchasers receive warrants to purchase shares equal to 200% of conversion shares (if subscribed by June 30, 2025) or 100% (if subscribed after). Warrants expire five years after issuance.
- Placement Agent Fees: Paulson Investment Company, LLC received a 12.0% cash fee of gross proceeds plus a $25,000 non-accountable expense, plus warrants equal to 12.0% of the conversion shares.
- Use of Proceeds: Funding for a Phase 1b/2 clinical trial, research and development, and working capital.
Material Changes and Transaction Structure
The filing details a material definitive agreement and the creation of a direct financial obligation. The transaction structure includes specific provisions to manage ownership concentration:
- Beneficial Ownership Limitations: If conversion would result in a holder owning more than 4.99% or 9.99% of outstanding shares, the holder receives pre-funded warrants with an exercise price of $0.01 instead of common stock.
- Reverse Split Trigger: Conversion is triggered 30 days after the effectiveness of a reverse split or on the one-year anniversary of issuance, whichever is earlier.
- Future Capacity: The company may continue offering additional notes and warrants on the same terms until a maximum of $5 million in gross proceeds is raised.
- Stockholder Approval: The company agreed to hold a special stockholder meeting to seek approval for the issuance of shares upon conversion.
Guidance, Risks, and Contingencies
Management intends to use the net proceeds to advance clinical trials and general corporate purposes. Key risks and contingencies identified include:
- Registration Requirements: The company must file a registration statement within 30 days of the conversion date and use commercially reasonable efforts to have it effective within 60 days.
- Nasdaq Compliance: Issuance of shares is capped to ensure compliance with Nasdaq Listing Rule 5635(d) regarding the number of shares issuable upon conversion.
- Unregistered Securities: The notes, warrants, and pre-funded warrants were sold pursuant to exemptions under Section 4(a)(2) of the Securities Act and/or Rule 506(c) of Regulation D and are not registered.
Investor Verification Checklist
- Verify the exact net proceeds after deducting the 12% placement fee and $25,000 expense.
- Confirm the timeline for the special stockholder meeting required to approve the conversion shares.
- Monitor the company's stock price relative to the $0.40 maximum conversion price cap.
- Check for the filing of the registration statement for resale of conversion shares within 30 days of the conversion date.
- Assess the dilution impact of the 200% or 100% warrant coverage and the 12% placement agent warrants.